https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2012-03-21 10:18:332016-12-01 16:42:32Astex Pharmaceuticals Announces March 27th Analyst and Investor Day Agenda
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2012-03-06 10:22:242016-12-01 16:42:35Eisai Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for Dacogen® (decitabine) for Injection sNDA in Acute Myeloid Leukemia
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2012-02-28 11:47:452016-12-01 16:42:42Astex Pharmaceuticals to Announce 2011 Fourth Quarter and Year-End Financial Results on March 5, 2012
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2012-02-16 11:49:492016-12-01 16:42:45Astex Pharmaceuticals to Host Annual Analyst and Investor Day on March 27, 2012
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2012-02-09 11:52:452016-12-01 16:42:48FDA’s Oncologic Drugs Advisory Committee (ODAC) Votes to not Support Benefit/Risk Profile of DACOGEN® (decitabine) in Acute Myeloid Leukemia
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2012-01-16 11:55:402016-12-01 16:42:52Astex Announces Early Transfer of Epigenetics Project to GSK
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
